
    
      This study is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
      evaluate the efficacy, safety, and tolerability of ANB019 compared with placebo in cancer
      subjects with EGFRi/MEKi-associated acneiform rash. This study will also characterize the
      pharmacokinetic (PK) profile of ANB019 and explore the immune response to ANB019 in subjects
      with EGFRi/MEKi-associated acneiform rash.
    
  